Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nuvo Pharmaceuticals Inc MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. see more

Bullboard (OTCQX:MRVFF)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Post by lscfaon May 11, 2020 10:20am

Q1 highlights

Q1 2020 Financial Highlights   For the three months ended March 31, 2020, adjusted total revenue(1) was $18.9 million, an increase of 11% compared to $17.1 million for the three ...more  
390
Discussion
Comment by Marathon11on May 11, 2020 9:51am

RE:RE:Insider buying continues

My guess is Buyout. Employment Agreements in the latest annual report with big payouts for "change of control". Contract for Harris (Chairman) was for 2019 but has been extended for 2020. In ...more  
201
Discussion
Comment by ValueCapon May 08, 2020 11:52pm

RE:Earnings Monday

I kind of hope the stock drops to 50 cents again so I can buy more lol. 
175
Discussion
Post by ValueCapon May 08, 2020 9:25pm

Earnings Monday

What to expect?  I think the comp from last year Q1 2019 as a baseline for Q1 2020, with adjusted revenue of 17.1 million, adjusted ebitda of 5.1 million.  Blexten and Cambia will have ...more  
406
Discussion
Comment by UglyKidStockon Mar 28, 2020 11:46am

RE:Insider buying continues

Of all of the stock bargains available in the market after this crash NRI insiders have bought their companies stock.   80,000 shares since earnings report.   Not a ton of money but a ...more  
414
Discussion
Comment by lscfaon Mar 04, 2020 6:12pm

RE:Launch of Generic Version of Vimovo in the United States

Maybe Dr Reddy has made a calculated risk. Begin sales now and grow big time and budget for a settlement with Nuvo of say $10 million US which Nuvo would probably agree to.  
255
Discussion
Post by midardon Mar 04, 2020 5:22pm

Launch of Generic Version of Vimovo in the United States

  ORIGINAL: Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States   2020-03-04 17:05 ET - News Release   ...more  
320
Discussion
Post by ValueCapon Mar 03, 2020 7:50pm

Insiders Buying

https://m.canadianinsider.com/node/7?menu_tickersearch=NRI+%7C+Nuvo+Pharmaceuticals+
328
Comment by lscfaon Feb 29, 2020 3:43pm

RE:Target Price

$2.30..... https://www.bloomburton.com/research/NRI20200226.pdf
215
Discussion
Post by Marathon11on Feb 29, 2020 11:35am

Target Price

Has BB published a new target price? Resultz US will be a big big deal in my opinion. Holding and accumulating until 2024-2025.
240
Discussion
Post by lscfaon Feb 27, 2020 7:36pm

Health Canada approval

https://www.newswire.ca/news-releases/nuvo-pharmaceuticals-r-announces-health-canada-approves-suvexx-tm-for-the-acute-treatment-of-migraine-842721618.html
196
Discussion
Post by lscfaon Feb 25, 2020 11:17pm

Transcript

https://seekingalpha.com/article/4326938-nuvo-pharmaceuticals-inc-nriff-ceo-jesse-ledger-on-q4-2019-results-earnings-call-transcript?part=single
163
Post by lscfaon Feb 25, 2020 9:41am

Presentation

https://www.nuvopharmaceuticals.com/wp-content/uploads/2020/02/02-25-2020_Investor-Presentation.pdf
173
Comment by lscfaon Feb 25, 2020 9:13am

RE:Great quarter and year end

synergies of merger too....
142
Discussion
Post by ValueCapon Feb 25, 2020 8:01am

Great quarter and year end

8.6 million quarterly ebitda vs estimate 7.8. Annual ebitda 28.1 million vs 26.1 estimate   Great Blexten and Cambia growth. Swiss approval of Pennsaid 2% and launch this year ...more  
248
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities